LCT appoints Chief Science and Medical Officer

Living Cell Technologies Limited
Company Announcement

LCT appoints Chief Science and Medical Officer

10 December, 2012 Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the appointment of Dr Paul Tan to the position of Chief Science and Medical Officer (CSMO).

As CSMO, Dr Tan is tasked with leading the company’s clinical trial programmes for DIABECELL® and NTCELL®. He will also lead the research and development and technology transfer teams at LCT, so that LCT has a growing pipeline of novel, breakthrough products entering clinical development to treat diseases of high unmet need.

Dr Tan has more than 18 years’ experience in senior roles in the biotechnology industry, leading research and development teams into clinical trials in the US, UK, New Zealand, Philippines, Brazil and Russia. He has managed relationships with regulatory bodies including Medsafe (NZ), the FDA (US) and the Centre for Disease Control (US). In both his executive and consulting roles Dr Tan has secured substantial government and private investor funding for the research and development of therapeutic products and he has successfully transferred multiple therapeutic products into a GMP manufacturing environment.

“Many will know that Dr Tan previously held senior executive roles at LCT from 2004 to late 2010,” said Dr Andrea Grant, Managing Director, LCT. “Since stepping down, Dr Tan has acted regularly as a senior consultant to LCT on research, clinical and regulatory matters. Paul has extensive knowledge of LCT’s people, science and therapeutic and regulatory strategy. Coupled with this he brings an intimate knowledge and an enviable reputation in the New Zealand and Australian biotechnology, government and health sectors. I’m truly excited to have him re-join the team.”

Emeritus Professor Bob Elliott, who has been acting CSMO since June this year, will now focus on his governance roles as a board member of LCT and Chair of the board of Diatranz Otsuka Limited, LCT’s joint venture with Otsuka Pharmaceutical Factory. Professor Elliott will also continue on the executive management team of LCT on a part-time basis as Director, Clinical Research and Innovation. As such, he will principally be providing key strategic advice on clinical development and research innovation matters.

Both the CSMO and the Director, Clinical Research and In
novation report to the Chief Executive.

ends

© Scoop Media